Research Article

Comparative Proteomic Analysis of Peritoneal Dialysate from Chronic Glomerulonephritis Patients

Table 1

Identification of 10 altered spots, of which 4 showed higher levels in the early-stage PD samples, while 6 had higher levels in the middle stage.

Spot numberaProtein nameSwiss-Prot accession no.Mr (E/T)b (kDa)pI (E/T)cNo. of identified peptidesSequence coverage (%)Mascot scoreFold change ± SDdAlteration (M/E)

P01Ig mu chain C regionP0187168/496.5/6.4510.2215 Down
P02Fibrinogen gamma chainP0267945/515.7/5.4611.8258 Down
P03C-reactive proteinP0274125/255.5/5.5416.2145 Down
P04C-reactive proteinP0274125/255.4/5.5520.1156 Down
P05Ig delta chain C regionP0188070/476.2/6.836.3124 Up
P06Alpha-1-antitrypsinP0100946/474.7/5.4612.8301 Up
P07Histidine-rich glycoproteinP0419653/595.6/7.046.7186 Up
P08Histidine-rich glycoproteinP0419653/595.7/7.058.4211 Up
P09Apolipoprotein A-IP0264725/315.3/5.6412.9201 Up
P10Serum amyloid P-componentP0274327/255.7/6.1624.5298 Up

aThe spot numbers are designated in Figures 2(a) and 2(b).
bMr (E/T): experimental observation of apparent molecular weight in 2-DE/theoretical molecular weight calculated from protein sequence database.
cpI (E/T): experimental observation of pI in 2-DE/theoretical pI calculated from protein sequence database.
dFold change and standard deviation calculated from the protein spot intensity in middle-stage samples (M) versus that in early-stage samples (E).